Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
- None.
- Total revenue decreased by 25% YoY to $18.1 million in Q4 2023.
- Net loss attributable to stockholders increased by 12% YoY to $11.1 million in Q4 2023.
- Adjusted EBITDA loss was $5.9 million in Q4 2023, a 7% decrease YoY.
- Total revenue for FY 2023 decreased by 23.3% to $76.4 million compared to FY 2022.
- Net loss attributable to stockholders for FY 2023 decreased by 15% to $37.3 million.
- The company is not providing full-year 2024 financial guidance at this time.
Insights
The announcement from Venus Concept Inc. regarding its financial results for the fourth quarter and fiscal year of 2023 indicates a notable decrease in cash burn, which is a positive signal for cost control and financial stability. The reduction in operating expenses by 20% year-over-year is a significant achievement, demonstrating the company's commitment to its Transformational Plan and restructuring efforts. The restructuring of debt obligations to defer payments and the conversion of convertible notes to preferred stock could potentially alleviate short-term liquidity pressures. However, the reported decrease in total revenue by 25% year-over-year raises concerns about the company's sales performance in the face of macroeconomic challenges. The increase in the proportion of revenue from the subscription model could suggest a strategic shift towards more predictable, recurring income streams, which might be appealing to investors seeking stability.
From a financial perspective, the announcement of not providing full-year guidance for 2024 due to ongoing discussions about strategic alternatives implies uncertainty about the company's future direction. This could lead to volatility in the stock price as investors reassess their expectations. The decision to withhold guidance might also reflect the company's focus on potential mergers, acquisitions, or asset sales, which could significantly alter its financial trajectory. Investors should monitor these developments closely, as they could have material impacts on the company's valuation and strategic positioning within the medical aesthetic technology sector.
The reported decrease in Venus Concept's system sales, particularly in international markets due to macroeconomic headwinds and credit market constraints, reflects broader industry trends where companies in the medical aesthetic sector are susceptible to economic fluctuations. The strategic shift towards a subscription model, with a higher percentage of total systems revenue derived from subscriptions, aligns with market demands for flexible payment options and could enhance customer retention. However, the overall decline in revenue suggests that the company may be losing market share or facing increased competition.
With the commercial launch of the new multi-application platform, Venus Versa Pro, in the U.S., Venus Concept is likely aiming to capture new market segments and differentiate its product offerings. The effectiveness of this strategy will depend on the platform's adoption rate and customer satisfaction. The rebranding initiative to Venus Aesthetic Intelligence indicates a pivot towards leveraging emerging technologies, which could resonate well with practitioners seeking innovative solutions. However, the success of these initiatives in driving revenue growth remains to be seen and the company's ability to navigate the competitive landscape will be critical for its long-term success.
The financial results of Venus Concept Inc. reflect a challenging period for the company, with a significant reduction in system sales. In the medical aesthetic technology industry, sales of systems are often seen as a bellwether for a company's health, as they represent not only immediate revenue but also future consumable sales and service contracts. The reported shift towards a higher proportion of subscription-based system revenue suggests an adaptation to market preferences, potentially offering a more stable, albeit lower, revenue stream over time. This could be a strategic move to build a more resilient business model in an industry where technology advancements and competitive pressures are constant.
The introduction of Venus Versa Pro and the rebranding to Venus Aesthetic Intelligence signal an investment in innovation and a focus on the integration of advanced technologies like AI, which could be instrumental in setting the company apart from competitors. However, the impact of these initiatives on the company's financial performance will depend on their market acceptance and the ability to effectively monetize these innovations. The ongoing evaluation of strategic alternatives suggests that the company is exploring various avenues to enhance shareholder value, which could involve leveraging its technological advancements for partnerships or other collaborative opportunities.
TORONTO, April 01, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2023.
Fourth Quarter and Fiscal Year 2023 Summary & Recent Progress:
- Company continues to execute against Transformational Plan and achieved primary objective of reducing cash burn by over
50% vs. prior year- Cash used in operations for fiscal year 2023 of
$12.9 million , down52% year-over-year, from$27.0 million in the prior year period - Cash system revenue for fiscal year 2023 represented approximately
67% of total systems and subscriptions revenue, compared to58% in the prior year period
- Cash used in operations for fiscal year 2023 of
- Macroeconomic headwinds and accelerated restructuring in international markets resulted in softer-than-expected system sales; total revenue of
$18.1 million , down$6.2 million , or25% , year-over-year; up$0.5 million , or3% , quarter-over-quarter - Operating expenses of
$19.7 million , including approximately$0.3 million of costs related to restructuring activities, down$5.0 million , or20% , year-over-year - GAAP net loss attributable to stockholders of
$11.1 million , up$1.2 million , or12% year-over-year - Adjusted EBITDA loss of
$5.9 million , down$0.4 million , or7% year-over-year - On October 5, 2023, the Company announced that it finalized an agreement with its lenders to restructure its existing debt obligations, improving the Company's overall financial position by deferring certain principal and interest payments under its senior debt and exchanging a portion of its convertible notes for preferred stock.
- On October 17, 2023, the Company announced a company-wide rebranding initiative, introducing Venus Aesthetic Intelligence (or "Venus AI") to reflect the new strategic vision for the Company and an enhanced focus on emerging technologies in aesthetics.
- On November 1, 2023, the Company announced the commercial launch of its new multi-application platform Venus Versa Pro in the United States.
- On January 24, 2024, the Company announced that its Board of Directors is evaluating potential strategic alternatives to maximize shareholder value. As part of the process, the Board is considering a full range of strategic alternatives, which may include one or more financings, mergers, reverse mergers, other business combinations, sales of assets, licensing or other transactions.
- On March 25, 2024, announced that it received a decision from the Nasdaq Hearings Panel granting its request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(b) on or before May 28, 2024, and certain other conditions.
Management Commentary:
“Our fourth quarter revenue results reflect softer-than-expected system sales in the U.S. due to macroeconomic conditions and tighter credit markets, and by the impact of our accelerated restructuring activities in certain international markets,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “We have successfully executed our strategic turnaround plan, and our efforts to reposition and restructure the business resulted in a
| Fourth Quarter and Twelve Months of 2023 Revenue by Region and by Product Type: | ||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (dollars in thousands) | (dollars in thousands) | |||||||||||||||
| Revenues by region: | ||||||||||||||||
| United States | $ | 11,789 | $ | 13,782 | $ | 43,454 | $ | 52,101 | ||||||||
| International | 6,343 | 10,504 | 32,900 | 47,396 | ||||||||||||
| Total revenue | $ | 18,132 | $ | 24,286 | $ | 76,354 | $ | 99,497 | ||||||||
| | Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (dollars in thousands) | (dollars in thousands) | |||||||||||||||
| Revenues by product: | ||||||||||||||||
| Subscription—Systems | $ | 6,064 | $ | 5,777 | $ | 20,504 | $ | 35,267 | ||||||||
| Products—Systems | 8,662 | 14,068 | 41,874 | 47,906 | ||||||||||||
| Products—Other (1) | 2,544 | 3,614 | 10,563 | 13,316 | ||||||||||||
| Services | 862 | 827 | 3,413 | 3,008 | ||||||||||||
| Total revenue | $ | 18,132 | $ | 24,286 | $ | 76,354 | $ | 99,497 | ||||||||
| (1) Products-Other include ARTAS procedure kits, Viva tips, Glide and other consumables. |
| Fourth Quarter 2023 Financial Results: | ||||||||||||||||||||||||||
| Three Months Ended December 31, | ||||||||||||||||||||||||||
| 2023 | 2022 | Change | ||||||||||||||||||||||||
| (in thousands, except percentages) | $ | % of Total | $ | % of Total | $ | % | ||||||||||||||||||||
| Revenues: | ||||||||||||||||||||||||||
| Subscription—Systems | $ | 6,064 | 33.4 | $ | 5,777 | 23.8 | $ | 287 | 5.0 | |||||||||||||||||
| Products—Systems | 8,662 | 47.8 | 14,068 | 57.9 | (5,406 | ) | (38.4 | ) | ||||||||||||||||||
| Products—Other | 2,544 | 14.0 | 3,614 | 14.9 | (1,070 | ) | (29.6 | ) | ||||||||||||||||||
| Services | 862 | 4.8 | 827 | 3.4 | 35 | 4.2 | ||||||||||||||||||||
| Total | $ | 18,132 | 100.0 | $ | 24,286 | 100.0 | $ | (6,154 | ) | (25.3 | ) | |||||||||||||||
Total revenue for the fourth quarter of 2023 decreased
Gross profit for the fourth quarter of 2023 decreased
Operating expenses for the fourth quarter of 2023 decreased
Operating loss for the fourth quarter of 2023 was
Net loss attributable to stockholders for the fourth quarter of 2023 was
As of December 31, 2023, the Company had cash and cash equivalents of
| Fiscal Year 2023 Financial Results: | ||||||||||||||||||||||||||
| Twelve Months Ended December 31, | ||||||||||||||||||||||||||
| 2023 | 2022 | Change | ||||||||||||||||||||||||
| (in thousands, except percentages) | $ | % of Total | $ | % of Total | $ | % | ||||||||||||||||||||
| Revenues: | ||||||||||||||||||||||||||
| Subscription—Systems | $ | 20,504 | 26.9 | $ | 35,267 | 35.5 | $ | (14,763 | ) | (41.9 | ) | |||||||||||||||
| Products—Systems | 41,874 | 54.8 | 47,906 | 48.1 | (6,032 | ) | (12.6 | ) | ||||||||||||||||||
| Products—Other | 10,563 | 13.8 | 13,316 | 13.4 | (2,753 | ) | (20.7 | ) | ||||||||||||||||||
| Services | 3,413 | 4.5 | 3,008 | 3.0 | 405 | 13.5 | ||||||||||||||||||||
| Total | $ | 76,354 | 100.0 | $ | 99,497 | 100.0 | $ | (23,143 | ) | (23.3 | ) | |||||||||||||||
Total revenue decreased by
Net loss attributable to stockholders for the twelve months ended December 31, 2023 decreased
Fiscal Year 2024 Financial Outlook:
Given the Company’s active dialogue with existing lenders and investors and the ongoing evaluation of strategic alternatives with various interested parties to maximize shareholder value, the Company is not providing full year 2024 financial guidance at this time. The Company expects total revenue for the three months ending March 31, 2024 of at least
Conference Call Details:
Management will host a conference call at 8:00 a.m. Eastern Time on April 1, 2024 to discuss the results of the quarter and fiscal year with a question-and-answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13744647. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.
For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13744647.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 12 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, but are not limited to, statements about our financial performance and metrics; the growth in demand for our systems and other products; the efficacy of the Venus Versa Pro; the contribution of the Venus Versa Pro to our revenue; the efficacy of the restructuring plan; the identification and efficacy of strategic alternatives to maximize shareholder value; the reduction in our cash burn; and our ability to regain compliance with the continued listing rules of the Nasdaq Capital Market. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part II Item 1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.
| Venus Concept Inc. Condensed Consolidated Balance Sheets (In thousands of U.S. dollars, except share and per share data) | ||||||||
| Year Ended, December 31, | ||||||||
| 2023 | 2022 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 5,396 | $ | 11,569 | ||||
| Accounts receivable, net of allowance of | 29,151 | 37,262 | ||||||
| Inventories | 23,072 | 23,906 | ||||||
| Prepaid expenses | 1,298 | 1,688 | ||||||
| Advances to suppliers | 5,604 | 5,881 | ||||||
| Other current assets | 1,925 | 3,702 | ||||||
| Total current assets | 66,446 | 84,008 | ||||||
| LONG-TERM ASSETS: | ||||||||
| Long-term receivables, net | 11,318 | 20,044 | ||||||
| Deferred tax assets | 1,032 | 947 | ||||||
| Severance pay funds | 573 | 741 | ||||||
| Property and equipment, net | 1,322 | 1,857 | ||||||
| Operating right-of-use assets, net | 4,517 | 5,862 | ||||||
| Intangible assets | 8,446 | 11,919 | ||||||
| Total long-term assets | 27,208 | 41,370 | ||||||
| TOTAL ASSETS | $ | 93,654 | $ | 125,378 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Trade payables | $ | 9,038 | $ | 8,033 | ||||
| Accrued expenses and other current liabilities | 12,437 | 16,667 | ||||||
| Current portion of long-term debt | 4,155 | 7,735 | ||||||
| Income taxes payable | 366 | 117 | ||||||
| Unearned interest income | 1,468 | 2,397 | ||||||
| Warranty accrual | 1,029 | 1,074 | ||||||
| Deferred revenues | 1,076 | 1,765 | ||||||
| Operating lease liabilities | 1,590 | 1,807 | ||||||
| Total current liabilities | 31,159 | 39,595 | ||||||
| LONG-TERM LIABILITIES: | ||||||||
| Long-term debt | 70,790 | 70,003 | ||||||
| Income tax payable | — | 374 | ||||||
| Accrued severance pay | 634 | 867 | ||||||
| Deferred tax liabilities | 15 | — | ||||||
| Unearned interest revenue | 671 | 957 | ||||||
| Warranty accrual | 334 | 408 | ||||||
| Operating lease liabilities | 3,162 | 4,221 | ||||||
| Other long-term liabilities | 338 | 215 | ||||||
| Total long-term liabilities | 75,944 | 77,045 | ||||||
| TOTAL LIABILITIES | 107,103 | 116,640 | ||||||
| Commitments and Contingencies (Note 9) | ||||||||
| STOCKHOLDERS’ EQUITY (DEFICIT) (Note 14): | ||||||||
| Common Stock, | 30 | 29 | ||||||
| Additional paid-in capital | 247,854 | 232,169 | ||||||
| Accumulated deficit | (261,903 | ) | (224,105 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | (14,019 | ) | 8,093 | |||||
| Non-controlling interests | 570 | 645 | ||||||
| (13,449 | ) | 8,738 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $ | 93,654 | $ | 125,378 | ||||
| Venus Concept Inc. Condensed Consolidated Statements of Operations (In thousands of U.S. dollars, except per share data) | |||||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
| Revenue | |||||||||||||||||||
| Leases | $ | 6,064 | $ | 5,777 | $ | 20,504 | $ | 35,267 | |||||||||||
| Products and services | 12,068 | 18,509 | 55,850 | 64,230 | |||||||||||||||
| 18,132 | 24,286 | 76,354 | 99,497 | ||||||||||||||||
| Cost of goods sold: | |||||||||||||||||||
| Leases | 679 | 1,366 | 4,312 | 9,435 | |||||||||||||||
| Products and services | 5,390 | 7,131 | 19,875 | 24,091 | |||||||||||||||
| 6,069 | 8,497 | 24,187 | 33,526 | ||||||||||||||||
| Gross profit | 12,063 | 15,879 | 52,167 | 65,971 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||
| Selling and marketing | 7,912 | 9,300 | 31,213 | 40,276 | |||||||||||||||
| General and administrative | 10,115 | 12,804 | 41,048 | 49,618 | |||||||||||||||
| Research and development | 1,670 | 2,573 | 8,197 | 10,953 | |||||||||||||||
| Total operating expenses | 19,697 | 24,678 | 80,476 | 100,847 | |||||||||||||||
| Loss from operations | (7,634) | (8,889 | ) | (28,309 | ) | (34,876 | ) | ||||||||||||
| Other expenses: | |||||||||||||||||||
| Foreign exchange loss | (674 | ) | (1,002 | ) | (295 | ) | 3,387 | ||||||||||||
| Finance expenses | 2,227 | 1,385 | 6,893 | 4,561 | |||||||||||||||
| Loss on disposal of subsidiaries | 97 | 1,482 | 174 | 1,482 | |||||||||||||||
| Loss on debt extinguishment | 2,040 | — | 2,040 | — | |||||||||||||||
| Loss before income taxes | (11,324) | (10,754 | ) | (37,121 | ) | (44,306 | ) | ||||||||||||
| Income tax (benefit) expense | (174) | (814 | ) | (71 | ) | (722 | ) | ||||||||||||
| Net loss | (11,150) | (9,940 | ) | (37,050 | ) | (43,584 | ) | ||||||||||||
| Net loss attributable to stockholders of the Company | (11,116) | (9,917 | ) | (37,250 | ) | (43,700 | ) | ||||||||||||
| Net income attributable to non-controlling interest | (34) | (23 | ) | 200 | 116 | ||||||||||||||
| Net loss per share: | |||||||||||||||||||
| Basic | $ | (2.01) | $ | (2.11 | ) | $ | (6.84 | ) | $ | (9.94 | ) | ||||||||
| Diluted | $ | (2.01) | $ | (2.11 | ) | $ | (6.84 | ) | $ | (9.94 | ) | ||||||||
| Weighted-average number of shares used in per share calculation: | |||||||||||||||||||
| Basic | 5,529 | 4,694 | 5,442 | 4,398 | |||||||||||||||
| Diluted | 5,529 | 4,694 | 5,442 | 4,398 | |||||||||||||||
| Venus Concept Inc. Condensed Consolidated Statements of Cash Flows (in thousands) | ||||||||
| Year Ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (37,050 | ) | $ | (43,584 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 4,115 | 4,463 | ||||||
| Stock-based compensation | 1,569 | 2,104 | ||||||
| Provision for bad debt | 1,350 | 7,337 | ||||||
| Provision for inventory obsolescence | 1,158 | 2,420 | ||||||
| Finance expenses and accretion | 2,206 | 414 | ||||||
| Deferred tax recovery | (69 | ) | (709 | ) | ||||
| Loss on sale of subsidiary | 174 | - | ||||||
| Loss on disposal of property and equipment | 10 | 158 | ||||||
| Loss on debt extinguishment | 2,040 | - | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable short- and long-term | 14,891 | 9,855 | ||||||
| Inventories | (324 | ) | (5,783 | ) | ||||
| Prepaid expenses | 390 | 1,049 | ||||||
| Advances to suppliers | 277 | (214 | ) | |||||
| Other current assets | 1,603 | 56 | ||||||
| Operating right-of-use assets, net | 1,345 | (5,862 | ) | |||||
| Other long-term assets | 47 | 200 | ||||||
| Trade payables | 1,005 | (385 | ) | |||||
| Accrued expenses and other current liabilities | (5,089 | ) | (3,647 | ) | ||||
| Current operating lease liabilities | (217 | ) | 1,807 | |||||
| Severance pay funds | 168 | 76 | ||||||
| Unearned interest income | (1,215 | ) | (679 | ) | ||||
| Long-term operating lease liabilities | (1,059 | ) | 4,221 | |||||
| Other long-term liabilities | (184 | ) | (277 | ) | ||||
| Net cash used in operating activities | (12,859 | ) | (26,980 | ) | ||||
| CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES: | ||||||||
| Purchases of property and equipment | (116 | ) | (336 | ) | ||||
| Net cash used in investing activities | (116 | ) | (336 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| 2022 Private Placement, net of costs of | - | 6,518 | ||||||
| 2023 Private Placement, net of costs of | 6,261 | - | ||||||
| Proceeds from issuance of common stock | 816 | 2,135 | ||||||
| Repayment of government assistance loans | - | (543 | ) | |||||
| Dividends from subsidiaries paid to non-controlling interest | (275 | ) | (124 | ) | ||||
| Proceeds from exercise of options | - | 23 | ||||||
| Net cash provided by financing activities | 6,802 | 8,009 | ||||||
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (6,173 | ) | (19,307 | ) | ||||
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of year | 11,569 | 30,876 | ||||||
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of year | $ | 5,396 | $ | 11,569 | ||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for income taxes | $ | 124 | $ | 329 | ||||
| Cash paid for interest | $ | 4,473 | $ | 4,147 | ||||
Use of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP measure defined as net income (loss) before foreign exchange loss, financial expenses, income tax expense (benefit), depreciation and amortization, stock-based compensation and non-recurring items for a given period. Adjusted EBITDA is not a measure of our financial performance under U.S. GAAP and should not be considered an alternative to net income or any other performance measures derived in accordance with U.S. GAAP. Accordingly, you should consider Adjusted EBITDA along with other financial performance measures, including net income, and our financial results presented in accordance with U.S. GAAP. Other companies, including companies in our industry, may calculate Adjusted EBITDA differently or not at all, which reduces its usefulness as a comparative measure. We understand that although Adjusted EBITDA is frequently used by securities analysts, lenders and others in their evaluation of companies, Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are: Adjusted EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments; Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; and although depreciation and amortization are non-cash charges, the assets being depreciated will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.
We believe that Adjusted EBITDA is a useful measure for analyzing the performance of our core business because it facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by changes in foreign exchange rates that impact financial assets and liabilities denominated in currencies other than the U.S. dollar, tax positions (such as the impact on periods or companies of changes in effective tax rates), the age and book depreciation of fixed assets (affecting relative depreciation expense), amortization of intangible assets, stock-based compensation expense (because it is a non-cash expense) and non-recurring items as explained below.
The following reconciliation of net (loss) income to Adjusted EBITDA for the periods presented:
| Venus Concept Inc. Reconciliation of Net loss to Non-GAAP Adjusted EBITDA | ||||||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||||
| Reconciliation of net loss to adjusted EBITDA | (in thousands) | (in thousands) | ||||||||||||||||||
| Net loss | $ | (11,150 | ) | $ | (9,937 | ) | $ | (37,050 | ) | $ | (43,584 | ) | ||||||||
| Foreign exchange loss | (674 | ) | (1,002 | ) | (295 | ) | 3,387 | |||||||||||||
| Loss on disposal of subsidiaries | 97 | 1,482 | 174 | 1,482 | ||||||||||||||||
| Loss on debt extinguishment | 2,040 | — | 2,040 | — | ||||||||||||||||
| Finance expenses | 2,227 | 1,385 | 6,893 | 4,561 | ||||||||||||||||
| Income tax (benefit) expense | (174 | ) | (814 | ) | (71 | ) | (722 | ) | ||||||||||||
| Depreciation and amortization | 1,073 | 1,070 | 4,115 | 4,463 | ||||||||||||||||
| Stock-based compensation expense | 355 | 552 | 1,569 | 2,104 | ||||||||||||||||
| Inventory Provision (1) | — | — | — | 1,388 | ||||||||||||||||
| Other adjustments (2) | 280 | 818 | 2,362 | 1,544 | ||||||||||||||||
| Adjusted EBITDA | $ | (5,926 | ) | $ | (6,347 | ) | $ | (20,263 | ) | $ | (25,377 | ) | ||||||||
(1) For the year ended December 31, 2022, the inventory provision represents a strategic review of our product offerings which culminated in a decision to discontinue production and sale of certain models and component parts, resulting in an inventory adjustment of
(2) For the year ended December 31, 2023, the other adjustments of
FAQ
What was Venus Concept's cash burn reduction achievement in FY 2023?
What was the total revenue for Venus Concept in Q4 2023?
What was the percentage change in adjusted EBITDA loss for Venus Concept in Q4 2023?
What strategic action did Venus Concept take on October 5, 2023, related to debt restructuring?
What strategic evaluation is Venus Concept's Board of Directors undertaking to maximize shareholder value?
